Top-line data from Lexicon Pharmaceuticals’ LX1031 Phase 2 study for IBS to be presented (News-Medical-Net)
Written by Admin on Tuesday, November 24th, 2009 in Uncategorized.
Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon’s senior vice president of clinical …
More: continued here